Vitamins and entacapone in levodopa-induced hyperhomocysteinemia: A randomized controlled study

Neurology

Volumn 66, Issue 12, 2006, Pages 1941-1943

  Postuma, R B ^a   Espay, A J ^b   Zadikoff, C ^b   Suchowersky, O ^c   Martin, W R W ^c   Lafontaine, A L ^a   Ranawaya, R ^c   Camicioli, R ^c   Lang, A E ^b  

^a MONTREAL GENERAL HOSPITAL   (Canada)

^b TORONTO WESTERN HOSPITAL   (Canada)

^c UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CYANOCOBALAMIN; ENTACAPONE; FOLIC ACID; HOMOCYSTEINE; LEVODOPA; PLACEBO; VITAMIN;

ABNORMALLY HIGH SUBSTRATE CONCENTRATION IN BLOOD; ADULT; AGED; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMENTIA; DISEASE PREDISPOSITION; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG INDUCED DISEASE; HEART DISEASE; HUMAN; HYPERHOMOCYSTEINEMIA; MULTICENTER STUDY; PARKINSON DISEASE; PRIORITY JOURNAL; RANDOMIZATION; RANDOMIZED CONTROLLED TRIAL; STROKE;

AGED; ANTIPARKINSON AGENTS; CANADA; CATECHOLS; DOUBLE-BLIND METHOD; DRUG COMBINATIONS; FEMALE; FOLIC ACID; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; LEVODOPA; MALE; MIDDLE AGED; PARKINSON DISEASE; PLACEBO EFFECT; TREATMENT OUTCOME; UNITED STATES; VITAMIN B 12; VITAMINS;

EID: 33745911598     PISSN: 00283878     EISSN: None     Source Type: Journal    
DOI: 10.1212/01.wnl.0000219815.83681.f7     Document Type: Article

References (10)

1. Homcysteine Studies Collaboration. Homocysteine and risk of ischemic heart disease and stroke: a meta-analysis. JAMA 2002;288:2015-2022.
2. Kelly PJ, Rosand J, Kistler JP, et al. Homocysteine, MTHFR 677C->T polymorphism, and risk of ischemic stroke: results of a meta-analysis. Neurology 2002;59:529-536.
3. Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG. MTHFR 677C->T polymorphism and risk of coronary heart disease: a meta-analysis. JAMA 2002;288:2023-2031.
4. de Lau LM, Koudstaal PJ, van Meurs JB, Uitterlinden AG, Hofman A, Breteler MM. Methylenetetrahydrofolate reductase C677T genotype and PD. Ann Neurol 2005;57:927-930.
5. Postuma RB, Lang AE. Homocysteine and levodopa: should Parkinson disease patients receive preventative therapy? Neurology 2004;63:886-891.
6. Lamberti P, Zoccolella S, Iliceto G, et al. Effects of levodopa and COMT inhibitors on plasma homocysteine in Parkinson's disease patients. Mov Disord 2005;20:69-72.
7. Gibb WR, Lees AJ. The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease. J Neurol Neurosurg Psychiatry 1988;51:745-752.
8. O'Suilleabhain, PE, Bottiglieri T, Dewey RB, Jr., Sharma, S, az-Arrastia, R. Modest increase in plasma homocysteine follows levodopa initiation in Parkinson's disease. Mov Disord 2004;19:1403-1408.
9. O'Suilleabhain, PE, Sung V, Hernandez C, et al. Elevated plasma homocysteine level in patients with Parkinson disease: motor, affective, and cognitive associations. Arch Neurol 2004;61:865-868.
10. Ostrem JL, Kang GA, Subramanian I, et al. The effect of entacapone on homocysteine levels in Parkinson disease. Neurology 2005;64:1482.